A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : DF / disoproxil fumarate

[Related PubMed/MEDLINE]
Total Number of Papers: 39
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   DF  (>> Co-occurring Abbreviation)
Long Form:   disoproxil fumarate
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2017 Tenofovir Alafenamide: A Review in Chronic Hepatitis B. AF, HBeAg, HBV
2016 Disrupted trabecular bone micro-architecture in middle-aged male HIV-infected treated patients. BV/TV, HR-pQCT
2015 Plasma Tenofovir, Emtricitabine, and Rilpivirine and Intracellular Tenofovir Diphosphate and Emtricitabine Triphosphate Pharmacokinetics following Drug Intake Cessation. IC, PBMCs, PK, PrEP, TFV-DP
2014 Changes in bone mineral density after 96 weeks of treatment with atazanavir/ritonavir or lopinavir/ritonavir plus tenofovir DF/emtricitabine in treatment-naive patients with HIV-1 infection: the CASTLE body composition substudy. BMD
2014 Continuing education case study quiz. ---
2014 Tenofovir during pregnancy in rats: a novel pathway for programmed hypertension in the offspring. RAAS, SBP
2013 Advances in Nucleotide Antiviral Development from Scientific Discovery to Clinical Applications: Tenofovir Disoproxil Fumarate for Hepatitis B. CHB, TAF, TDF
2013 Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection. HIV-1
2013 Pharmacokinetic interactions between lersivirine and zidovudine, tenofovir disoproxil fumarate/emtricitabine and abacavir/lamivudine. ---
10  2012 Randomized, placebo-controlled trial of tenofovir disoproxil fumarate in adolescents with chronic hepatitis B. CHB, HBV
11  2012 Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. HBV
12  2011 Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1. ---
13  2011 Cost effectiveness of tenofovir disoproxil fumarate for the treatment of chronic hepatitis B from a Canadian public payer perspective. CHB, HBeAg
14  2011 Efficacy, adherence and tolerability of once daily tenofovir DF-containing antiretroviral therapy in former injecting drug users with HIV-1 receiving opiate treatment: results of a 48-week open-label study. IVDU
15  2009 Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy. HIV-1, NRTIs
16  2009 Improvements in cheek volume in lipoatrophic individuals switching away from thymidine nucleoside reverse transcriptase inhibitors. ABC, DEXA, NRTIs
17  2008 Efficacy and safety of once-daily regimens in the treatment of HIV infection. HAART, NNRTI
18  2008 Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. HBeAg, HBV
19  2007 The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years. EAP, SAEs
20  2006 A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy. ---
21  2006 Evaluation of oral tenofovir disoproxil fumarate and topical tenofovir GS-7340 to protect infant macaques against repeated oral challenges with virulent simian immunodeficiency virus. SIV
22  2006 Multidrug resistance-associated protein 2 (MRP2) affects hepatobiliary elimination but not the intestinal disposition of tenofovir disoproxil fumarate and its metabolites. mono, mono, MRP2, MRP2
23  2006 Serious renal impairment occurs rarely with use of tenofovir DF. CLCr, SCr
24  2006 Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. HIV
25  2005 Assessment of drug-drug interactions between tenofovir disoproxil fumarate and the nonnucleoside reverse transcriptase inhibitors nevirapine and efavirenz in HIV-infected patients. ---
26  2005 In vitro combination studies of tenofovir and other nucleoside analogues with ribavirin against HIV-1. HCV, RBV
27  2005 Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy for pediatric HIV infection. BMD
28  2005 Treatment of chronic hepatitis B in HIV co-infected patients. HAART, HBV, HIV, IFN
29  2004 Effect of tenofovir disoproxil fumarate on the pharmacokinetics and pharmacodynamics of total, R-, and S-methadone. SOWS
30  2004 Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. ---
31  2004 Fatal lactic acidosis associated with coadministration of didanosine and tenofovir disoproxil fumarate. HIV
32  2004 Genotypic and phenotypic predictors of the magnitude of response to tenofovir disoproxil fumarate treatment in antiretroviral-experienced patients. TAMs
33  2004 Interactions between atazanavir-ritonavir and tenofovir in heavily pretreated human immunodeficiency virus-infected patients. HIV, NRTI
34  2003 Single-dose and steady-state pharmacokinetics of tenofovir disoproxil fumarate in human immunodeficiency virus-infected children. HIV
35  2002 Rapid communication: acute renal failure associated with tenofovir: evidence of drug-induced nephrotoxicity. ---
36  2002 Tenofovir disoproxil fumarate: a nucleotide reverse transcriptase inhibitor for the treatment of HIV infection. ---
37  2002 Topical administration of low-dose tenofovir disoproxil fumarate to protect infant macaques against multiple oral exposures of low doses of simian immunodeficiency virus. SIV
38  2001 Hydroxyurea does not enhance the anti-HIV activity of low-dose tenofovir disoproxil fumarate. ---
39  2001 Tenofovir, adefovir, and zidovudine susceptibilities of primary human immunodeficiency virus type 1 isolates with non-B subtypes or nucleoside resistance. HIV-1